Aspirin Paracetamol Tablet Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions containing aspirin and paracetamol face challenges in achieving rapid absorption and stability, as aspirin is susceptible to hydrolytic degradation when combined with alkaline agents like calcium carbonate, leading to the formation of undesirable degradation products like salicylic acid, and existing formulations are complex and costly to manufacture.
Innovation Solution
A pharmaceutical composition comprising intragranular paracetamol with calcium carbonate of a specific particle size (d50 > 11 µm) and aspirin as extragranular components, along with a hydrophilic colloid, which enhances dissolution properties without the need for physical separation of alkaline and acidic components, improving stability and manufacturing efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If aspirin is combined with alkaline agents like calcium carbonate to enhance dissolution and absorption, then the dissolution rate and absorption speed are improved, but aspirin undergoes hydrolytic degradation forming salicylic acid
Solution Approach 1:
The formulation segregates aspirin and calcium carbonate into different granule populations. Aspirin is incorporated into granules with specific carriers while calcium carbonate remains as separate particles or in different granules. This physical segmentation prevents direct contact and chemical interaction between the acidic aspirin and alkaline calcium carbonate, eliminating hydrolytic degradation while preserving the dissolution-enhancing effects of both components.
Solution Approach 2:
Pharmaceutically acceptable carriers and excipients act as intermediaries between aspirin and calcium carbonate. These carriers physically separate the two components while allowing both to coexist in the same tablet matrix. The intermediary materials prevent direct acid-base reactions while maintaining the individual functional properties of aspirin and calcium carbonate for enhanced dissolution and absorption.
2Stability of the object's composition
If physical separation methods like double pouches or multi-layer tablets are used to prevent interaction between acidic and alkaline components, then formulation stability is improved, but device complexity and manufacturing cost increase
Solution Approach 1:
The invention merges aspirin and calcium carbonate into a single unified tablet formulation rather than using separate physical compartments. By incorporating both components into the same tablet matrix with appropriate carriers and granulation techniques, the formulation achieves stability without the complexity of multi-layer structures, capsules within capsules, or separate packaging systems.
Solution Approach 2:
Different regions of the tablet have different compositions and properties. Aspirin is localized within specific granules or carrier matrices while calcium carbonate is distributed separately or in different granule populations. This local differentiation allows both components to coexist without interaction while maintaining a simple single-tablet structure.
3Speed
If fine particle size calcium carbonate is used to enhance dissolution, then dissolution rate is improved, but aspirin degradation increases due to greater surface area contact
Solution Approach 1:
The formulation segments fine particle size calcium carbonate into separate granule populations from aspirin-containing granules. This segmentation allows the fine calcium carbonate particles to provide enhanced dissolution through large surface area while preventing contact with aspirin, as they are physically separated by the granule structure and carriers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves enhanced release and stability of aspirin and paracetamol, maintaining stability below 3% salicylic acid levels during storage, with improved manufacturing economics and patient compliance.
Implementation Method 1
aspirin is susceptible to hydrolytic degradation when combined with alkaline agents like calcium carbonate, leading to the formation of undesirable degradation products like salicylic acid
Implementation Method 2
A pharmaceutical composition comprising intragranular paracetamol with calcium carbonate of a specific particle size (d50 > 11 µm) and aspirin as extragranular components, along with a hydrophilic colloid, which enhances dissolution properties
Data Source
AI summary
A pharmaceutical composition, suitably in the form of a tablet, is described comprising intragranular and extragranular components. The intragranular components comprise a pharmaceutically effective amount of paracetamol, calcium carbonate provided in the form of particles having a d50 greater than 11 µm, and at least one binding agent and the extragranular components comprise a pharmaceutically effective amount of aspirin, and at least one hydrophilic colloid. Optionally the compositions comprise caffeine.